214 related articles for article (PubMed ID: 27035536)
41. Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist.
Phelps LE; Brutsche N; Moral JR; Luckenbaugh DA; Manji HK; Zarate CA
Biol Psychiatry; 2009 Jan; 65(2):181-4. PubMed ID: 18996507
[TBL] [Abstract][Full Text] [Related]
42. Comparative Effects of LY3020371, a Potent and Selective Metabotropic Glutamate (mGlu) 2/3 Receptor Antagonist, and Ketamine, a Noncompetitive
Witkin JM; Mitchell SN; Wafford KA; Carter G; Gilmour G; Li J; Eastwood BJ; Overshiner C; Li X; Rorick-Kehn L; Rasmussen K; Anderson WH; Nikolayev A; Tolstikov VV; Kuo MS; Catlow JT; Li R; Smith SC; Mitch CH; Ornstein PL; Swanson S; Monn JA
J Pharmacol Exp Ther; 2017 Apr; 361(1):68-86. PubMed ID: 28138040
[TBL] [Abstract][Full Text] [Related]
43. Comparison of ketamine vs. ECT in major depressive disorder: need for ECT standard dosing and duration parameters.
Campion P
Psychiatry Res; 2015 Jan; 225(1-2):216. PubMed ID: 25511507
[No Abstract] [Full Text] [Related]
44. Speed of response to electroconvulsive therapy compared with ketamine.
Kellner CH; ; Lisanby SH; Weiner R; Prudic J; Rudorfer MV; Young RC; Petrides G; McCall WV; Husain M; Greenberg RM; Knapp RG
Psychiatry Res; 2015 Jan; 225(1-2):215. PubMed ID: 25511506
[No Abstract] [Full Text] [Related]
45. How does ketamine elicit a rapid antidepressant response?
Kavalali ET; Monteggia LM
Curr Opin Pharmacol; 2015 Feb; 20():35-9. PubMed ID: 25462290
[TBL] [Abstract][Full Text] [Related]
46. The complexities of depression.
Strakowski SM
Curr Psychiatry Rep; 2012 Dec; 14(6):608-9. PubMed ID: 23011786
[No Abstract] [Full Text] [Related]
47. Role of nitric oxide signaling in the antidepressant mechanism of action of ketamine: A randomized controlled trial.
Bevilacqua L; Charney A; Pierce CR; Richards SM; Jha MK; Glasgow A; Brallier J; Kirkwood K; Bagiella E; Charney DS; Murrough JW
J Psychopharmacol; 2021 Feb; 35(2):124-127. PubMed ID: 33522376
[TBL] [Abstract][Full Text] [Related]
48. Serum interleukin-6 is a predictive biomarker for ketamine's antidepressant effect in treatment-resistant patients with major depression.
Yang JJ; Wang N; Yang C; Shi JY; Yu HY; Hashimoto K
Biol Psychiatry; 2015 Feb; 77(3):e19-e20. PubMed ID: 25104172
[No Abstract] [Full Text] [Related]
49. Monitoring ketamine treatment response in a depressed patient via peripheral mammalian target of rapamycin activation.
Denk MC; Rewerts C; Holsboer F; Erhardt-Lehmann A; Turck CW
Am J Psychiatry; 2011 Jul; 168(7):751-2. PubMed ID: 21724677
[No Abstract] [Full Text] [Related]
50. An integrative view on the cell-type-specific mechanisms of ketamine's antidepressant actions.
Lewis V; Rurak G; Salmaso N; Aguilar-Valles A
Trends Neurosci; 2024 Mar; 47(3):195-208. PubMed ID: 38220554
[TBL] [Abstract][Full Text] [Related]
51. [Ketamine for treatment of depression?].
Vinberg M
Ugeskr Laeger; 2013 Sep; 175(37):2089. PubMed ID: 24011202
[No Abstract] [Full Text] [Related]
52. What is the mechanism of Ketamine's rapid-onset antidepressant effect? A concise overview of the surprisingly large number of possibilities.
Strasburger SE; Bhimani PM; Kaabe JH; Krysiak JT; Nanchanatt DL; Nguyen TN; Pough KA; Prince TA; Ramsey NS; Savsani KH; Scandlen L; Cavaretta MJ; Raffa RB
J Clin Pharm Ther; 2017 Apr; 42(2):147-154. PubMed ID: 28111761
[TBL] [Abstract][Full Text] [Related]
53. Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity.
Gerhard DM; Wohleb ES; Duman RS
Drug Discov Today; 2016 Mar; 21(3):454-64. PubMed ID: 26854424
[TBL] [Abstract][Full Text] [Related]
54. Comparing the actions of lanicemine and ketamine in depression: key role of the anterior cingulate.
Downey D; Dutta A; McKie S; Dawson GR; Dourish CT; Craig K; Smith MA; McCarthy DJ; Harmer CJ; Goodwin GM; Williams S; Deakin JF
Eur Neuropsychopharmacol; 2016 Jun; 26(6):994-1003. PubMed ID: 27133029
[TBL] [Abstract][Full Text] [Related]
55. The role of mTOR in depression and antidepressant responses.
Abelaira HM; Réus GZ; Neotti MV; Quevedo J
Life Sci; 2014 Apr; 101(1-2):10-4. PubMed ID: 24582593
[TBL] [Abstract][Full Text] [Related]
56. Case series: Antidepressant effects of low-affinity and low-trapping NMDA receptor antagonists did not predict response to ketamine in seven subjects.
Lepow L; Luckenbaugh DA; Park L; Henter ID; Zarate CA
J Psychiatr Res; 2017 Mar; 86():55-57. PubMed ID: 27914292
[No Abstract] [Full Text] [Related]
57. Potential involvement of serotonergic signaling in ketamine's antidepressant actions: A critical review.
du Jardin KG; Müller HK; Elfving B; Dale E; Wegener G; Sanchez C
Prog Neuropsychopharmacol Biol Psychiatry; 2016 Nov; 71():27-38. PubMed ID: 27262695
[TBL] [Abstract][Full Text] [Related]
58. Is there anything really novel on the antidepressant horizon?
Murrough JW; Charney DS
Curr Psychiatry Rep; 2012 Dec; 14(6):643-9. PubMed ID: 22996298
[TBL] [Abstract][Full Text] [Related]
59. Targeting glutamate signalling in depression: progress and prospects.
Murrough JW; Abdallah CG; Mathew SJ
Nat Rev Drug Discov; 2017 Jul; 16(7):472-486. PubMed ID: 28303025
[TBL] [Abstract][Full Text] [Related]
60. Two case studies of patients with major depressive disorder given low-dose (subanesthetic) ketamine infusions.
Correll GE; Futter GE
Pain Med; 2006; 7(1):92-5. PubMed ID: 16533209
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
